AU7122501A - Aryl sulfonamides as serotonin antagonist for the treatment of obesity - Google Patents

Aryl sulfonamides as serotonin antagonist for the treatment of obesity

Info

Publication number
AU7122501A
AU7122501A AU7122501A AU7122501A AU7122501A AU 7122501 A AU7122501 A AU 7122501A AU 7122501 A AU7122501 A AU 7122501A AU 7122501 A AU7122501 A AU 7122501A AU 7122501 A AU7122501 A AU 7122501A
Authority
AU
Australia
Prior art keywords
treatment
obesity
serotonin antagonist
aryl sulfonamides
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU7122501A
Other languages
English (en)
Inventor
Patrizia Caldirola
Sukhwinder Jossan
Kjell S Sakariassen
Jan Svartengren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of AU7122501A publication Critical patent/AU7122501A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU7122501A 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity Pending AU7122501A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002739A SE0002739D0 (sv) 2000-07-21 2000-07-21 New use
PCT/SE2001/001652 WO2002008179A1 (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity

Publications (1)

Publication Number Publication Date
AU7122501A true AU7122501A (en) 2002-02-05

Family

ID=20280564

Family Applications (2)

Application Number Title Priority Date Filing Date
AU7122501A Pending AU7122501A (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
AU2001271225A Ceased AU2001271225B2 (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001271225A Ceased AU2001271225B2 (en) 2000-07-21 2001-07-19 Aryl sulfonamides as serotonin antagonist for the treatment of obesity

Country Status (16)

Country Link
EP (1) EP1301475B1 (enExample)
JP (1) JP2004504377A (enExample)
KR (2) KR100828977B1 (enExample)
CN (1) CN100339073C (enExample)
AT (1) ATE346040T1 (enExample)
AU (2) AU7122501A (enExample)
CA (1) CA2411195A1 (enExample)
CY (1) CY1106026T1 (enExample)
DE (1) DE60124717T2 (enExample)
DK (1) DK1301475T3 (enExample)
ES (1) ES2277930T3 (enExample)
NO (1) NO20030297L (enExample)
NZ (1) NZ523158A (enExample)
PT (1) PT1301475E (enExample)
SE (1) SE0002739D0 (enExample)
WO (1) WO2002008179A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204720D0 (en) * 2002-02-28 2002-04-17 Glaxo Group Ltd Novel use
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
CL2008003232A1 (es) * 2007-11-02 2009-11-27 Abbott Gmbh & Co Kg Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
EP2432770A1 (en) 2009-04-30 2012-03-28 Abbott GmbH & Co. KG Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
JP2012525355A (ja) * 2009-04-30 2012-10-22 アボット ゲーエムベーハー ウント カンパニー カーゲー セロトニン５−ｈｔ６受容体の調節に応答する障害を治療するのに適したベンゼンスルホンアニリド化合物
KR20120016639A (ko) 2009-04-30 2012-02-24 애보트 게엠베하 운트 콤파니 카게 세로토닌 5-ｈｔ6 수용체의 조절에 반응하는 장애를 치료하는 데 적합한 ｎ-페닐-(피페라지닐 또는 호모피페라지닐)-벤젠설폰아미드 또는 벤젠설포닐-페닐-(피페라진 또는 호모피페라진) 화합물
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
ES2413911B1 (es) * 2011-12-15 2014-05-14 Universidad De Zaragoza Agente inhibidor de la agregación del peptido beta amiloide.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9627006D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents
PL338016A1 (en) * 1997-07-11 2000-09-25 Smithkline Beecham Plc Novel chemical compounds
JPH11171856A (ja) * 1997-09-26 1999-06-29 Fujirebio Inc アシルスルホンアミド誘導体
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
CA2315614C (en) * 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles

Also Published As

Publication number Publication date
ATE346040T1 (de) 2006-12-15
DE60124717D1 (de) 2007-01-04
HK1057886A1 (zh) 2004-04-23
DE60124717T2 (de) 2007-09-13
AU2001271225B2 (en) 2006-09-07
NZ523158A (en) 2004-04-30
CA2411195A1 (en) 2002-01-31
CN1443161A (zh) 2003-09-17
EP1301475B1 (en) 2006-11-22
ES2277930T3 (es) 2007-08-01
CN100339073C (zh) 2007-09-26
KR20080016725A (ko) 2008-02-21
DK1301475T3 (da) 2007-04-02
KR20030016413A (ko) 2003-02-26
KR100880806B1 (ko) 2009-01-30
PT1301475E (pt) 2007-02-28
KR100828977B1 (ko) 2008-05-13
SE0002739D0 (sv) 2000-07-21
WO2002008179A1 (en) 2002-01-31
EP1301475A1 (en) 2003-04-16
NO20030297D0 (no) 2003-01-20
CY1106026T1 (el) 2011-04-06
JP2004504377A (ja) 2004-02-12
NO20030297L (no) 2003-01-20

Similar Documents

Publication Publication Date Title
ATE440603T1 (de) 8-hydroxychinolinderivate
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
NO20083207L (no) Inhibitorer av IAP
GB0112348D0 (en) Compounds
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
DE602006017694D1 (de) C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
ATE324371T1 (de) N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten
MXPA04006031A (es) Compuestos para el tratamiento de trastornos inflamatorios.
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
MXPA05009303A (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr.
DE60232173D1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
AU7122501A (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MXPA03005374A (es) Carbazoles antitumorales.
NO20030500D0 (no) Dihydroporfyrinderivater og deres anvendelse
NO20063790L (no) Substituerte azetidin sammensetninger som cyclooxygenase-1-cyclooxygenase-2-inhibitorer, og deres fremstilling og anvendelse som medikamenter
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.
DK1370526T3 (da) Diamider som inhiberer tryptase og faktor Xa-virkning
SE0103539D0 (sv) New Use